首页> European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)> Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

导出原文传递

翻译打印收藏纠错

第一作者： Eckstein, Markus

作者： Eckstein, Markus ^[1] ; Erben, Philipp ^[2] ; Kriegmair, Maximilian C. ^[3] ; Worst, Thomas S. ^[4] ; Weiss, Cleo-Aron ^[5] ; Wirtz, Ralph M. ^[6] ; Wach, Sven ^[7] ; Stoehr, Robert ^[8] ; Sikic, Danijel ; Geppert, Carol I. ; Weyerer, Veronika ; Bertz, Simone ; Breyer, Johannes ; Otto, Wolfgang ; Keck, Bastian ; Burger, Maximilian ; Taubert, Helge ; Weichert, Wilko ; Wullich, Bernd ; Bolenz, Christian ; Hartmann, Arndt ; Erlmeier, Franziska

作者单位： Univ Ulm, Dept Urol, Ulm, Germany ^[1] Tech Univ Munich, Inst Pathol, Munich, Germany ^[2] Heidelberg Univ, Med Fac Mannheim, Dept Urol Mannheim, Mannheim, Germany ^[3] Univ Regensburg, Dept Urol, Regensburg, Germany ^[4] Heidelberg Univ, Inst Pathol, Med Fac Mannheim, Mannheim, Germany ^[5] Friedrich Alexander Univ Erlangen Nurnberg, Dept Urol & Pediat Urol, Erlangen, Germany ^[6] STRATIFYER Mol Pathol GmbH, Cologne, Germany ^[7] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Pathol, Krankenhausstr 8-10 ^[8]

关键词 Bladder cancer Urothelial carcinoma PD-L1 assay PD-L1 PD-1 Checkpoint inhibition

发布时间 2019-06-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交